Finance committee  The short answer is, a number of companies that are a part of Canada's research-based pharmaceutical companies are also participating in BIOTECanada. Our membership is probably a little broader because we don't just have those leading global companies. We also have small, emergin

Finance committee  I'll take a first stab at that. I'll leave it to my colleagues there as well. Do we know what's happening next year? No, we don't, but what we do know that is good for Canadians is that the $100 million through the national immunization strategy goes to vaccines and goes to trea

Finance committee  In addition to flow-through shares, Canada works on a number of leading innovative sectors, and it boasts a world-class portfolio of research organizations and leading companies developing innovative vaccines for debilitating diseases. Our companies are doing much to help Canad

Finance committee  Our final recommendation is to call for support for industrial biotechnology companies that are developing new, dedicated biomass crops, transitioning our forestry industries into centres of biorefining, and developing renewable materials for our auto and housing sectors, all hel

Health committee  To answer Dr. Bennett's question on whether it is a regulatory change, the answer is yes. We know there are a number of examples they're working on, which Durhane talked about, in terms of how you can define the product, how you would treat it, what kind of evidence and data you'

Health committee  For sure. It speaks to her third point here: Establish a Canadian Plan for Rare Disorders that is based on international best practices.... That speaks to the network you build to share that expertise. And whether it's Health Canada centred, as in other areas, for instance,

Health committee  Thank you. I think Maureen's and Dr. Urbain's stories are great examples of a symptom of a challenge that Canada presents and that other countries don't have, which Durhane mentioned. If you think about it, Canadian patients are at a disadvantage. Researchers are at a disadvanta

Health committee  Thank you. Bonjour. Good morning. My name is Peter Brenders. I'm the president and CEO of BIOTECanada. We're the national organization representing biotechnology companies in this country. There are 21 today working on rare disorder treatments. So I'm pleased to be here.

Health committee  I think what you see is a strengthened diversity of opinions that come to the board and make the board and its work more strategic, more relevant. It speaks to helping to bring what our directions are in terms of currency of research and where it's going and what's going to be re

Health committee  I think Dr. Rouleau said it well. You have, certainly, great perspectives. People have an opportunity to think and hear different perspectives, much as you would see around a committee like this. You have different perspectives, and it's great for a discussion. But at the end of

Health committee  I am.

Health committee  I think it's a fabulous representation of the collaboration that goes on in Canada. Advocacy is a component of what we do to help build Canada's industry and research institutes. We work very well with CIHR, with NRC, NSERC, a host of universities--the University of Toronto, the

Health committee  Well, to answer that question now, if I might--

Health committee  As for the implications of conflict of interest, I think Dr. Rouleau emphasized that very clearly--

Health committee  Okay. I think the vital potential in hitting these key results, and the speed out there, is going to reflect in the partnerships we have. The vital potential of CIHR will only be realized if they're enabled, as part of their mandate, to pursue leadership with global expertise. D